| 4:00–8:00 PM | Registration |
| 6:00–8:00 PM | Welcome Mixer |
| 7:00–8:00 AM | Breakfast |
| 8:00–9:00 AM | Welcome and Keynote Address |
| Carine Boustany †, Boehringer Ingelheim Drug Discovery in Fibrosis |
| 9:00–11:15 AM | Developing Novel Therapeutics in Fibrotic Disease |
| Thomas A Wynn †, Pfizer Anti-Inflammatory Therapeutics in Organ Fibrosis |
| Paul J. Yaworsky †, Mediar Therapeutics Targeting EphrinB2 and WISP1 in Liver and Pulmonary Fibrosis |
| Catherine Hines †, GlaxoSmithKline Biomarkers and Imaging as Readouts in Clinical Testing |
| Short Talk(s) Chosen from Abstracts |
| 9:30–9:50 AM | Coffee Break |
| 11:15–12:15 PM | Meet the Editors |
| 12:15–1:00 PM | Poster Setup |
| 12:15–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing |
| 2:30–4:30 PM | Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
| Short Talks Chosen from Abstracts |
| 4:30–5:00 PM | Coffee Available |
| 5:00–7:00 PM | From Identification of Novel Therapies to Early Clinical Testing in Fibrosis |
| Lisa Lancaster †, Vanderbilt University Medical Center Endpoints in Clinical Trials in Fibrosis |
| Rebekka Schneider †, Erasmus MC From Single Cell Genomics to Novel Targets in Fibrotic Disease and Clinical Testing |
| Frank A. Anania †, US Food and Drug Administration Regulatory Steps Towards Approval of Novel Antifibrotic Therapies |
| Short Talk(s) Chosen from Abstracts |
| 7:00–8:00 PM | Social Hour with Dinner |
| 7:30–10:00 PM | Posters |
| 7:00–8:00 AM | Breakfast |
| 8:00–11:00 AM | Mapping Fibrotic Disease using Single Cell and Spatial Genomics |
| Rafael Kramann, RWTH Aachen University Mapping Kidney and Cardiac Fibrosis to Identify Novel Therapeutic Targets |
| Neil C. Henderson, Institute of Regeneration and Repair, University of Edinburgh Spatial Mapping of Human Liver Fibrosis |
| Bethan Psaila †, University of Oxford Single Cell Mapping of Myelofibrosis |
| Benjamin D. Humphreys †, Washington University Single Cell and Spatial Genomics to Map Kidney Fibrosis |
| Short Talk(s) Chosen from Abstracts |
| 9:00–9:20 AM | Coffee Break |
| 11:00–12:00 PM | Panel Discussion 1: How to Launch a Startup |
| Rafael Kramann, RWTH Aachen University |
| Rebekka Schneider, Erasmus MC |
| Neil C. Henderson, Institute of Regeneration and Repair, University of Edinburgh |
| Paul J. Yaworsky †, Mediar Therapeutics |
| 12:00–1:00 PM | Poster Setup |
| 12:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing |
| 3:00–4:30 PM | Career Roundtable |
| 4:30–5:00 PM | Coffee Available |
| 5:00–7:00 PM | Fibrosis in Cancer and Aging |
| Natalie J. Torok †, Stanford University The Role of Matrix in Liver Cancer Progression and Aging |
| Simon Mendez-Ferrer †, University of Cambridge Mechanisms of Fibrosis Hematopoietic Malignancies |
| Melanie Koenigshoff †, University of Pittsburgh Role of Senescence and Aging in Pulmonary Fibrosis |
| Short Talk(s) Chosen from Abstracts |
| 7:00–8:00 PM | Social Hour with Dinner |
| 7:30–10:00 PM | Posters |
| 7:00–8:00 AM | Breakfast |
| 8:00–11:00 AM | Organ Specific and Conserved Mechanisms of Organ Fibrosis |
| Jörg H.W. Distler †, University Hospital Düsseldorf Mechanisms of Pulmonary and Skin Fibrosis |
| Vincent F Fiore †, Boehringer Ingelheim Mechanisms of Fibrosis in IBD, Boehringer Ingelheim |
| Katalin Susztak †, University of Pennsylvania Mechanisms of Kidney Fibrosis |
| Kory J. Lavine †, Washington University School of Medicine Mechanisms of Cardiac Fibrosis |
| Short Talk(s) Chosen from Abstracts |
| 9:00–9:20 AM | Coffee Break |
| 11:00–12:00 PM | Panel Discussion 2: Why Are We not Seeing Progress / Therapeutic Success in Some Areas? What Are We Missing and How can We Address these Challenges/ Lessons from Clinical Trials? |
| 12:00–5:00 PM | On Own for Lunch |
| 2:30–4:30 PM | Symposia Spotlight 2: AI & Big Data in Drug Development |
| Short Talks Chosen from Abstracts |
| 4:30–5:00 PM | Coffee Available |
| 5:00–6:45 PM | Need for Multimodal Therapies, New Modalities and Lessons Learned from Clinical Trials |
| Grant Budas †, Gilead Multimodal Therapies for Fibrotic Disease |
| Shelia M. Violette †, Q32 Bio Immunotherapies and New Modalities for Fibrotic Disease |
| Scott L Friedman †, Icahn School of Medicine at Mount Sinai Lessons Learned from Clinical Trials and Regulatory Aspects in Fibrotic Disease |
| Short Talk(s) Chosen from Abstracts |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
| 7:00–8:00 PM | Social Hour with Dinner |
| 8:00–11:00 PM | Entertainment |
| 8:00–11:00 PM | Cash Bar |
| 12:00–11:59 PM | Departure |